Form 4: Voyager Therapeutics Director Receives Stock Option Grant

Voyager Therapeutics, Inc. reports a stock option grant to Director Michael J. Higgins, exercisable at $3.43 with a 10-year expiration.

Summary

• Michael J. Higgins, a Director at Voyager Therapeutics, Inc., was granted a stock option on June 9, 2026.
• The option allows for the purchase of 30,000 shares of common stock at an exercise price of $3.43 per share.
• This option is part of the company's 2025 Stock Incentive Plan and aligns with the director compensation policy.
• The option vests over one year from the grant date or until the next annual stockholder meeting, contingent on continued service as a director.
• The option has an expiration date of June 9, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director as part of compensation, with no immediate financial impact or significant strategic news.

Positives

• Director compensation aligns with equity incentives through stock options.
• The stock option grant provides potential upside for a key company insider.
• Vesting schedule encourages continued service and commitment to the company.

Risks

• The value of the stock option is subject to the future performance of Voyager Therapeutics' stock price.
• Continued service as a director is a condition for vesting, implying potential risk if service is terminated.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The stock option grant implies a belief in the future value of the company's stock.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as stock options, is a common practice in the biotechnology and pharmaceutical sectors to attract and retain key talent, especially directors and executives, aligning their interests with shareholders.

Corporate Governance

Related Party Transactions

• The stock option grant to Director Michael J. Higgins is a related party transaction, as it involves a director of the company.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with shareholders, potentially motivating performance. However, it also represents potential future dilution if options are exercised.
• Employees: This filing does not directly impact employees, but it reflects the company's compensation strategy for its board.
• Management: The filing is a routine disclosure related to board compensation and governance.

Next Steps

• Michael J. Higgins is expected to continue his service as a director for Voyager Therapeutics, Inc.
• The stock option will vest according to the schedule outlined in the filing.
• Voyager Therapeutics, Inc. will continue to operate under its 2025 Stock Incentive Plan.

Key Dates

Keywords

Voyager Therapeutics, VYGR, Form 4, Stock Option, Director Compensation, Equity Incentive, SEC Filing, Beneficial Ownership